Jeffrey B. Kindler was appointed Director of Praxis Precision Medicines, Inc., effective January 8, 2026. As of November 14, 2026, Praxis Precision Medicines, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 8, 2026 to February 10, 2026, naming 1 appointment (Form 8-K, February 10, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Praxis Precision Medicines, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Praxis Precision Medicines, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-08 to 2026-02-10. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Praxis Precision Medicines, Inc. files it.
Also on the record for Praxis Precision Medicines, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD | 5.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Baker Bros. Advisors LP | 6.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD | 8.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Biotech Private Investments, LLC | 0.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 7.7% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.09% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by ORBIS INVESTMENT MANAGEMENT LTD | 5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 7.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Steven A. Cohen | 6.1% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 3.83% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Praxis Precision Medicines, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Praxis Precision Medicines, Inc. and the records around it.
Praxis Precision Medicines, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- ORBIS INVESTMENT MANAGEMENT LTD also filed stake reports on 23 other companies: RXO, Inc. (Nov 2026), National CineMedia, Inc. (Sep 2026), BBB FOODS INC (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Praxis Precision Medicines, Inc.
Get an email when Praxis Precision Medicines, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Praxis Precision Medicines, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Praxis Precision Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Praxis Precision Medicines, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 26 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-10 | In | Director | 2026-01-08 | 8-K/A, 2026-02-10 | |
| 2026-01-08 | Reported | not named in the filing | 8-K, 2026-01-08 |
Who leads Praxis Precision Medicines, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Jeffrey B. Kindler, appointed, effective 2026-01-08 (filed 2026-02-10).
New leaders reset buying decisions — get the Full Report on Praxis Precision Medicines, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Praxis Precision Medicines, Inc., with the record behind each one.
Find candidates like Director at Praxis Precision Medicines, Inc.Every change, in the filing's words
Appointed: Jeffrey B. Kindler, Director, effective 2026-01-08
On January 8, 2026, Praxis Precision Medicines, Inc. (the "Company") filed a Current Report on Form 8-K (the "Initial 8-K") disclosing that the Board of Directors of the Company (the "Board") elected Jeffrey B. Kindler and Stuart A. Arbuckle to the Board, each as a Class II director, effective January 8, 2026.
- At the time of filing the Initial 8-K, the Board had not made a determination regarding any committee assignments for Mr. Kindler or Mr. Arbuckle.
Reported
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- Appointment of Megan Sniecinski as Chief Operating Officer On January 8, 2026, Praxis Precision Medicines, Inc. (the "Company") announced the appointment of Megan Sniecinski as Chief Operating Officer of the Company, effective January 1, 2026 (the "Effective Date").
- Ms. Sniecinski, age 45, served as Chief Business Officer of the Company from December 2021 through December 2025.
- Prior to joining the Company, she served as chief business officer at BioCryst Pharmaceuticals from 2019 to 2021, overseeing corporate development, global medical affairs, program management and global supply chain.
- From 2017 to 2019, she was senior vice president of business operations and program management at PTC Therapeutics, where she led established and grew the program management function and led business development during the company's transition toward becoming fully integrated, and commercial stage organization.
- Before joining PTC, Ms. Sniecinski spent more than a decade at Merck serving in a diverse set of operational and strategic roles supporting their manufacturing operations, commercial and G&A divisions, with increasing responsibility, culminating as director of business development and strategic partnerships at Merck Vaccines.
- Ms. Sniecinski received a B.S. in chemical engineering from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania.
Tools for this story
Each opens in a new tab, filled in for Praxis Precision Medicines, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
